Active ingredientRavidasvir DihydrochlorideCat. No. P-R019-001CAS 1303533-81-4Family · Pharmaceutical analytical standards
Ravidasvir
An antiviral that blocks the NS5A protein of the hepatitis C virus, used together with sofosbuvir for chronic hepatitis C in adults: in 2021 it was registered in Malaysia, conditionally, and in Egypt. This family brings together the active ingredient and other impurities.
Did you know?It was the first hepatitis C medicine developed through 'South-South' collaboration between non-profit organisations and organisations in developing countries: its clinical trials were run in Egypt, Malaysia and Thailand.
Go to the active ingredient →Active ingredientRavidasvir DihydrochlorideCat. No. P-R019-001CAS 1303533-81-4
ImpurityRavidasvir Impurity ACat. No. P-R019-002CAS 1228552-45-1
ImpurityRavidasvir Impurity BCat. No. P-R019-003CAS 1807684-63-4
ImpurityRavidasvir Impurity ECat. No. P-R019-004CAS 1228670-34-5
ImpurityRavidasvir Impurity HCat. No. P-R019-005
ImpurityRavidasvir Impurity ICat. No. P-R019-006
ImpurityRavidasvir Impurity JCat. No. P-R019-007
ImpurityRavidasvir Impurity KCat. No. P-R019-008
ImpurityRavidasvir Impurity LCat. No. P-R019-009
ImpurityRavidasvir Impurity MCat. No. P-R019-010CAS 1312611-60-1
ImpurityRavidasvir Impurity NCat. No. P-R019-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.